Cancer is the leading cause of death in the EU, with 2.7M diagnoses and 1.3M deaths in 2020. Effective removal of cancerous tissue through endoscopic surgery is challenging because of limited visual and absent tactile information, along with the limitations of current imaging technologies, which make it difficult for surgeons to differentiate between different types of tissue. For this market, Thericon developed a disruptive rMSI (real-time multispectral imaging) platform providing surgeons with multi-parametric images that help with effective removal of cancerous tissue and reduction of cancer recurrence in patients. Thericon’s technology is a paradigm shift in cancer treatment and it will give a new hope for the millions of people affected by this tremendous plague.